Abivax's Phase 3 ABTECT Maintenance Trial Of Obefazimod Met Primary Endpoint Of Clinical Remission And All Key Secondary Endpoints At Week 44 In Ulcerative Colitis

Loading news article.

Abivax's Phase 3 ABTECT Maintenance Trial Of Obefazimod Met Primary Endpoint Of Clinical Remission And All Key Secondary Endpoints At Week 44 In Ulcerative Colitis | WAPE

Abivax's Phase 3 ABTECT Maintenance Trial Of Obefazimod Met Primary Endpoint Of Clinical Remission And All Key Secondary Endpoints At Week 44 In Ulcerative Colitis

Article summary

Related companies

Comments —